Table 2.
Peak visual acuity after fluocinolone acetonide implant segmented by baseline visual acuity and duration of diabetic macular edema (a) and peak central retinal thickness after fluocinolone acetonide implant segmented by baseline central retinal thickness (b).
| (a) | ||||||
|
N *
(Studies) |
Mean Follow-
Up (Months) |
Mean DME †
Duration (Years) |
Mean Baseline VA ‡ (Letters) |
Mean Peak
VA (Letters) |
Mean Peak VA Gain (Letters) | |
| Baseline VA (letters) | ||||||
| <50 letters | 14 | 18.6 | 3.9 | 43.7 | 54.7 | 11.0 |
| 50–60 letters | 10 | 22.4 | 2.4 | 54.2 | 61.4 | 7.7 |
| >60 letters | 5 | 19.2 | 2.7 | 63.4 | 70.4 | 7.0 |
| DME duration (years) | ||||||
| ≤2 years | 7 | 24.0 | 2.0 | 59.6 | 68.3 | 8.7 |
| 2–4 years | 14 | 20.9 | 3.1 | 47.1 | 56.4 | 9.4 |
| >4 years | 4 | 15.0 | 5.9 | 53.2 | 58.3 | 5.1 |
| (b) | ||||||
|
N *
(Studies) |
Mean Follow-
Up (Months) |
Mean DME †
Duration (Years) |
Mean Baseline CRT § (µm) |
Mean Peak
CRT (µm) |
Mean Peak CRT Decrease (%) | |
| Baseline CRT (µm) | ||||||
| <400 µm | 2 | 18.0 | 2.9 | 349 | 285 | 18 |
| 400–600 µm | 20 | 22.0 | 3.3 | 505 | 328 | 34 |
| >600 µm | 5 | 14.0 | 2.7 | 640 | 361 | 44 |
* Number; † Diabetic macular edema; ‡ Visual acuity; § Central Retinal Thickness.